To explore the underlying mechanisms responsible for the scFv1C9-induced inhibition of tumour growth, a cyclin-dependent kinase 2 (CDK2) inhibitor, SU9516, was used as a positive control in the treatment of cells. This evidence concerns the gene CDK2 and neoplasm.